PRPeptide Evidence ReferenceEVIDENCE-GRADED · EDUCATIONAL
Educational reference only — not medical advice. Nothing is sold on this site. Research compounds are not for human use.
Home>>Peptides>>IGF-1 DES
Preclinical WADA prohibitedGH / growth factors

IGF-1 DES

A truncated variant of IGF-1 (des 1-3) with reduced binding-protein affinity and increased receptor potency, studied in laboratory settings.

CompoundIGF-1 DES
CategoryTruncated IGF-1 analog
ClassGrowth Hormone and Growth Factors
Evidence tierPreclinical
WADA statusProhibited in sport (or falls under a prohibited class) — see the WADA reference table
Sold on this siteNo — this is a reference database

Overview

This entry covers IGF-1 DES, a truncated igf-1 analog, graded "Preclinical" in this catalog's evidence system. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.

A truncated variant of IGF-1 (des 1-3) with reduced binding-protein affinity and increased receptor potency, studied in laboratory settings.

Mechanism of Action

Removal of the N-terminal tripeptide increases potency at the IGF-1 receptor by avoiding binding-protein sequestration; the analog is far more active than native IGF-1 in vitro.

Research and Evidence

No human clinical trials; the compound exists in cell-culture and preclinical pharmacology literature only.

Evidence in context: the Growth Hormone and Growth Factors class page collects the shared evidence themes and study-reading guidance for this category.

Safety and Side Effects

Same category concerns as other potent mitogens — no human safety data. Prohibited in sport.

Educational notice: this entry describes published research and, where they exist, regulator labels. It is not medical advice and not a recommendation for use. Research-grade compounds have no verified human-safety data.

Frequently Asked Questions

What is the evidence tier of IGF-1 DES?

IGF-1 DES is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.

Is IGF-1 DES an approved medicine?

No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.

Where can I read the primary studies for IGF-1 DES?

The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.

References

  1. ClinicalTrials.gov — search for IGF-1 DES studies (none registered). [source]
  2. WADA Prohibited List. [source]
EM
Dr. Elena Marsh, PhDMolecular Pharmacology · Lead Editor

Written and maintained by the editorial team. Medically reviewed by Dr. James Okafor, MD (Internal Medicine).

Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.

Advertisement